Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Can comply with one of the following groups:~   1. Negative control group: Must have no history of exposure to a TB index case, and have no signs or symptoms of TB~  2. Positive control group: Confirmed TB disease within the last 3 years by sputum smear microscopy and/or Culture, Gene Xpert or PCR~  3. Close contact group: Must be in close contact with a pulmonary smear positive TB index case for more than 6 hours/day for at least five days~  4. Occasional contact group: Must be in contact with a pulmonary sputum smear positive TB index case between 6 hours/week and 6 hours/day~2. Is between 6 weeks - 65 years of age~3. Participant, parent or legal guardian has provided signed informed consent~4. Is willing and likely to comply with the trial procedures~5. Is prepared to grant authorized persons access to their medical records~Exclusion Criteria:~1. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. Mumps Measles Rubella (MMR), yellow fever, oral typhoid vaccines)~2. Has been tuberculin tested less than 12 months prior to the day of inclusion~3. Is pregnant, breastfeeding or intending to get pregnant within the trial period~4. Is a female of child bearing potential (12 years of age or older having had their first menstruation) not willing to use effective barrier (including spermicidal gel), hormonal or intrauterine contraceptive measures within the trial period~5. Has an active disease affecting the lymphoid organs except for HIV (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)~6. Has a current skin condition which interferes with the reading of the C-Tb and Tuberculin PPD RT23 SSI e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites~7. Has a condition where blood drawings pose more than minimal risk for the participant, such as haemophilia, other coagulation disorders, or significantly impaired venous access~8. Current participation in another clinical trial with an investigational or non investigational drug or device, which in the opinion of investigator may interfere with this trial drug~9. Has participated in previous clinical trials investigating injections with ESAT-6 and/or CFP-10 antigens~10. Has a condition which in the opinion of the investigator is not suitable for participation in the trial

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 0.1 µg/0.1 mL C-Tb (Type: EXPERIMENTAL): The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
- 2 T.U. Tuberculin PPD RT 23 SSI (Type: ACTIVE_COMPARATOR): The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete